Cibc World Market Inc. Invests $1.23 Million in Ascendis Pharma A/S $ASND

Cibc World Market Inc. acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,168 shares of the biotechnology company’s stock, valued at approximately $1,226,000.

A number of other hedge funds have also bought and sold shares of ASND. First Horizon Advisors Inc. bought a new stake in Ascendis Pharma A/S during the second quarter valued at $41,000. Jones Financial Companies Lllp raised its position in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in shares of Ascendis Pharma A/S by 291.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 262 shares during the period. Farther Finance Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 115.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 256 shares in the last quarter. Finally, Toth Financial Advisory Corp grew its stake in Ascendis Pharma A/S by 33.7% during the third quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 150 shares during the period.

Ascendis Pharma A/S Trading Down 0.8%

Shares of Ascendis Pharma A/S stock opened at $216.32 on Tuesday. The company has a market capitalization of $13.41 billion, a P/E ratio of -49.16 and a beta of 0.44. The stock has a fifty day simple moving average of $215.04 and a 200 day simple moving average of $205.71. Ascendis Pharma A/S has a 12-month low of $124.06 and a 12-month high of $242.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The firm had revenue of $290.38 million for the quarter, compared to analysts’ expectations of $285.35 million. On average, analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on ASND shares. Wolfe Research started coverage on Ascendis Pharma A/S in a report on Tuesday, November 18th. They set a “peer perform” rating and a $255.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. Barclays initiated coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 27th. They set an “overweight” rating and a $342.00 price objective on the stock. Finally, Oppenheimer raised their target price on Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $284.00.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.